Nebula Research & Development’s Regeneron Pharmaceuticals REGN Stock Holding History

Nebula Research & Development’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,575	Closed	-$2.4M	–	691
2025 Q2	$2.4M	Buy	4,575 +892	+24%	+$498K	0.2%	151
2025 Q1	$2.34M	Buy	3,683 +2,080	+130%	+$1.43M	0.22%	125
2024 Q4	$1.14M	Sell	1,603 -1,957	-55%	-$1.64M	0.13%	252
2024 Q3	$3.74M	Buy	+3,560	New	+$3.96M	0.45%	11
2024 Q2	–	Sell	-469	Closed	-$451K	–	1008
2024 Q1	$451K	Sell	469 -1,079	-70%	-$1.03M	0.1%	391
2023 Q4	$1.36M	Buy	+1,548	New	+$1.27M	0.41%	37

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nebula Research & Development's REGN Position: Q3 2025 in Review

Nebula Research & Development sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 4,575 shares — an estimated $2.4M sold.

Nebula Research & Development first reported a position in REGN in Q4 2023 and held it in 6 quarters. The position peaked at $3.74M in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Nebula Research & Development reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 4,575 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $2.4M.
Nebula Research & Development first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Nebula Research & Development's Regeneron Pharmaceuticals position peaked at $3.74M in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.